IFNγ/IL-10 ratio, however, was significantly different between NSCLC and COPD patients (P<0.001), with a median ratio of 0.84 in the NSCLC group versus 1.11 in the COPD cohort (Figure 2). This evidence concerns the gene IFNG and non-small cell lung carcinoma.